Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIa trial of RP 5063 in patients with pulmonary arterial hypertension (PAH)

Next Previous
X
Search
Trial Profile

A phase IIa trial of RP 5063 in patients with pulmonary arterial hypertension (PAH)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilaroxazine (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Jan 2023 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in 2023.
    • 27 Jul 2022 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in Q4 2022.
    • 15 Nov 2021 According to a Reviva Pharmaceuticals media release, the company is planning regulatory to the U.S. Food and Drug Administration (FDA) by the end of Q1 2022 to initiate this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top